[1]王松涛,周国民.诱导多能干细胞在视网膜疾病研究中的应用[J].眼科新进展,2017,37(6):587-590.[doi:10.13389/j.cnki.rao.2017.0149]
　WANG Song-Tao,ZHOU Guo-Min.Application of induced pluripotent stem cells in retinal diseases[J].Recent Advances in Ophthalmology,2017,37(6):587-590.[doi:10.13389/j.cnki.rao.2017.0149]
点击复制

诱导多能干细胞在视网膜疾病研究中的应用/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年6期
页码:
587-590
栏目:
文献综述
出版日期:
2017-06-05

文章信息/Info

Title:
Application of induced pluripotent stem cells in retinal diseases
作者:
王松涛; 周国民
453003　河南省新乡市，新乡医学院人体解剖学教研室（王松涛）；200032　上海市，复旦大学上海医学院人体解剖与组织胚胎学系（王松涛，周国民）
Author(s):
WANG Song-Tao; ZHOU Guo-Min
Department of Human Anatomy，Xinxiang Medical University（WANG Song-Tao），Xinxiang 453003，Henan Province，China；Department of Human Anatomy，Histology and Embryology，Shanghai Medical College of Fudan University （WANG Song-Tao，ZHOU Guo-Min），Shanghai 200032，China
关键词:
诱导多能干细胞; 视网膜疾病; 再生医学; 细胞移植
Keywords:
induced pluripotent stem cell; retinal disease; regenerative medicine; cell transplantation
分类号:
R774
DOI:
10.13389/j.cnki.rao.2017.0149
文献标志码:
A
摘要:
诱导多能干细胞（induced pluripotent stem cells，iPSCs）是成体细胞通过重编程而获得的一类具有胚胎干细胞相似特性和功能的细胞。近年来，iPSCs在再生医学和干细胞研究领域备受关注，尤其是患者特异源性iPSCs，来源方便、无免疫排斥和伦理学问题，同时还可以保留特定个体基因型，为再生医学以及细胞移植疗法提供了新的细胞来源。目前，iPSCs在视网膜疾病研究领域取得了长足的进步。本文主要对iPSCs向视网膜色素上皮细胞、感光细胞和神经节细胞的诱导分化及细胞移植研究、安全性评价等方面进行综述，探讨iPSCs在视网膜疾病研究中的应用和前景。
Abstract:
Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cells that can be generated from adult somatic cells.They have similar characteristics and function to embryonic stem cells (ESCs).Over the past decade，iPSCs were widely concerned in regenerative medicine and stem cell field.Especially the patient specific iPSCs have several advantages over ESCs，such as convenient source，do not exist immune rejection and ethical issues，even keep certain individual genotype.At present，tremendous progress have been made about the application of iPSCs in a variety of retinal diseases.Here，this article reviews pluripotent stem cell sources of RPE，photoreceptors and retinal ganglion cells and current transplantation strategies，the safety problems and prospects.

参考文献/References:

［1］　HUMAYUN MS，DE JUAN E，DEL CERRO M，DAGNELIE G，RADNER W，SADDA SR，et al.Human neural retinal transplantation［J］.Invest Ophthalmol Vis Sci，2000，41（10）：3100-3106.
［2］　RADTKE ND，ARAMANT RB，SEILER MJ，PETRY HM，PIDWELL D.Vision change after sheet transplant of fetal retina with retinal pigment epithelium to a patient with retinitis pigmentosa［J］.Arch Ophthalmol，2004，122（8）：1159-1165.
［3］　BALLIOS BG，VAN DER KOOY D.Biology and therapeutic potential of adult retinal stem cells［J］.Can J Ophthalmol，2010，45（4）：342-351.
［4］　LAMBA D，KARL M，REH T.Neural regeneration and cell replacement：a view from the eye［J］.Cell Stem Cell，2008，2（6）：538-549.
［5］　LAMBA DA，GUST J，REH TA.Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice［J］.Cell Stem Cell，2009，4（1）：73-79.
［6］　ROWLAND TJ，BUCHHOLZ DE，CLEGG DO.Pluripotent human stem cells for the treatment of retinal disease［J］.J Cell Physiol，2012，227（2）：457-466.
［7］　ZARBIN M.Cell-based therapy for degenerative retinal disease［J］.Trends Mol Med，2016，22（2）：115-134.
［8］　WILEY LA，BURNIGHT ER，DELUCA AP，ANFINSON KR，CRANSTON CM，KAALBERG EE，et al.cGMP production of patient-specific iPSCs and photoreceptor precursor cells to treat retinal degenerative blindness［J］.Sci Rep，2016，6：30742.
［9］　EHMANN D，SHAHLAEE A，HO AC.Cell therapy for retinal disease［J］.Curr Opin Ophthalmol，2016，27（3）：185-190.
［10］　NGUYEN HV，LI Y，TSANG SH.Patient-specific iPSCs-derived rpe for modeling of retinal diseases［J］.J Clin Med，2015，4（4）：567-578.
［11］　WILEY LA，BURNIGHT ER，SONGSTAD AE，DRACK AV，MULLINS RF，STONE EM，et al.Patient-specific induced pluripotent stem cells （iPSCs） for the study and treatment of retinal degenerative diseases［J］.Prog Retin Eye Res，2015，44：15-35.
［12］　OKANO H.Investigation of pathophysiology of parkinson’s disease using iPS cells technology［J］.Rinsho Shinkeigaku，2012，52（11）：899.
［13］　FUKUDA K.Chronic heart failure：progress in diagnosis and treatment.Topics：III.Progress in prevention，control and treatment：8.Establishment of novel therapy for congestive heart failure using human iPS cell-derived regenerated cardiomyocytes［J］.Nihon Naika Gakkai Zasshi，2012，101（2）：415-423.
［14］　OKAMOTO S，TAKAHASHI M.Induction of retinal pigment epithelial cells from monkey iPS cells［J］.Invest Ophthalmol Vis Sci，2011，52（12）：8785-8790.
［15］　BUCHHOLZ DE，HIKITA ST，ROWLAND TJ，FRIEDRICH AM，HINMAN CR，JOHNSON LV，et al.Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells［J］.Stem Cells，2009，27（10）：2427-2434.
［16］　OSAKADA F，JIN ZB，HIRAMI Y，IKEDA H，DANJYO T，WATANABE K，et al.In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction［J］.J Cell Sci，2009，122（17）：3169-3179.
［17］　KROHNE TU，WESTENSKOW PD，KURIHARA T，FRIEDLANDER DF，LEHMANN M，DORSEY AL，et al.Generation of retinal pigment epithelial cells from small molecules and OCT4-reprogrammed human induced pluripotent stem cells［J］.Stem Cells Transl Med，2012，1（2）：96-109.
［18］　PHILLIPS MJ，WALLACE KA，DICKERSON SJ，MILLER MJ，VERHOEVEN AD，MARTIN JM，et al.Blood-derived human iPS cells generate optic vesicle-like structures with the capacity to form retinal laminae and develop synapses［J］.Invest Ophthalmol Vis Sci，2012，53（4）：2007-2019.
［19］　WESTENSKOW PD，MORENO SK，KROHNE TU，KURIHARA T，ZHU SY，ZHANG ZN，et al.Using flow cytometry to compare the dynamics of photoreceptor outer segment phagocytosis in iPS-derived RPE cells［J］.Invest Ophthalmol Vis Sci，2012，53（10）：6282-6290.
［20］　LI Y，TSAI YT，HSU CW，EROL D，YANG J，WU WH，et al.Long-term safety and efficacy of human induced pluripotent stem cell （iPS） grafts in a preclinical model of retinitis pigmentosa［J］.Mol Med，2012，18：1312-1319.
［21］　YANG J，CAI B，GLENCER P，LI Z，ZHANG X，LI X.Induced pluripotent stem cells and outer retinal disease［J］.Stem Cells Int，2016，2016：2850873.
［22］　YANG J，LI Y，CHAN L，TSAI YT，WU WH，NGUYEN HV，et al.Validation of genome-wide association study （GWAS）-identified disease risk alleles with patient-specific stem cell lines［J］.Hum Mol Genet，2014，23（13）：3445-3455.
［23］　KAMAO H，MANDAI M，OKAMOTO S，SAKAI N，SUGA A，SUGITA S，et al.Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application［J］.Stem Cell Rep，2014，2（2）：205-218.
［24］　NAKANO T，ANDO S，TAKATA N，KAWADA M，MUGURUMA K，SEKIGUCHI K，et al.Self-formation of optic cups and storable stratified neural retina from human ESCs［J］.Cell Stem Cell，2012，10（6）：771-785.
［25］　HIRAMI Y，OSAKADA F，TAKAHASHI K，OKITA K，YAMANAKA S，IKEDA H，et al.Generation of retinal cells from mouse and human induced pluripotent stem cells［J］.Neurosci Lett，2009，458（3）：126-131.
［26］　TUCKER BA，PARK IH，QI SD，KLASSEN HJ，JIANG C，YAO J，et al.Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice［J］.PLoS One，2011，6（4）：e18992.
［27］　ZHONG X，GUTIERREZ C，XUE T，HAMPTON C，VERGARA MN，CAO LH，et al.Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs［J］.Nat Commun，2014，5：4047.
［28］　SLUCH VM，DAVIS CH，RANGANATHAN V，KERR JM，KRICK K，MARTIN R，et al.Differentiation of human ESCs to retinal ganglion cells using a CRISPR engineered reporter cell line［J］.Sci Rep，2015，5：16595.
［29］　PARAMESWARAN S，BALASUBRAMANIAN S，BABAI N，QIU F，EUDY JD，THORESON WB，et al.Induced pluripotent stem cells generate both retinal ganglion cells and photoreceptors：therapeutic implications in degenerative changes in glaucoma and age-related macular degeneration［J］.Stem Cells，2010，28（4）：695-703.
［30］　CHEN M，CHEN Q，SUN X，SHEN W，LIU B，ZHONG X，et al.Generation of retinal ganglion-like cells from reprogrammed mouse fibroblasts［J］.Invest Ophthalmol Vis Sci，2010，51（11）：5970-5978.
［31］　DENG F，CHEN M，LIU Y，HU H，XIONG Y，XU C，et al.Stage-specific differentiation of iPSCs toward retinal ganglion cell lineage［J］.Mol Vis，2016，22：536-547.
［32］　TANAKA T，YOKOI T，TAMALU F，WATANABE S，NISHINA S，AZUMA N.Generation of retinal ganglion cells with functional axons from human induced pluripotent stem cells［J］.Invest Ophthalmol Vis Sci，2016，57(7)：3348-3359.
［33］　FINGERT JH，ROBIN AL，STONE JL，ROOS BR，DAVIS LK，SCHEETZ TE，et al.Copy number variations on chromosome 12 q14 in patients with normal tension glaucoma［J］.Hum Mol Genet，2011，20（12）：2482-2494.
［34］　TUCKER BA，SOLIVAN-TIMPE F，ROOS BR，ANFINSON KR，ROBIN AL，WILEY LA，et al.Duplication of TBK1 stimulates autophagy in ipscs-derived retinal cells from a patient with normal tension glaucoma［J］.J Stem Cell Res Ther，2014，3（5）：161.
［35］　LIU Y，LEVINE B.Autosis and autophagic cell death：the dark side of autophagy［J］.Cell Death Differ，2015，22（3）：367-376.
［36］　KURODA T，YASUDA S，KUSAKAWA S，HIRATA N，KANDA Y，SUZUKI K，et al.Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells［J］.PLoS One，2012，7（5）：e37342.
［37］　COMYN O，LEE E，MACLAREN RE.Induced pluripotent stem cell therapies for retinal disease［J］.Curr Opin Neurol，2010，23（1）：4-9.

相似文献/References:

[1]付校楠 彭惠.眼底自发荧光技术在部分视网膜疾病中的应用进展[J].眼科新进展,2013,33(4):000.
[2]李筱荣.干细胞在视网膜疾病中的应用研究进展[J].眼科新进展,2013,33(10):000.
[3]孙荧,李颖,范丹.自噬与视网膜疾病的研究现状[J].眼科新进展,2016,36(5):494.[doi:10.13389/j.cnki.rao.2016.0132]
　SUN Ying,LI Ying,FAN Dan.Recent advances in autophagy and retinal diseases[J].Recent Advances in Ophthalmology,2016,36(6):494.[doi:10.13389/j.cnki.rao.2016.0132]
[4]许卓珺,余克明,庄菁.诱导多能干细胞向神经视网膜细胞定向分化的研究进展[J].眼科新进展,2016,36(9):885.[doi:10.13389/j.cnki.rao.2016.0238]
　XU Zhuo-Jun,YU Ke-Ming,ZHUANG Jing.Research progress on differentiation from induced pluripotent stem cells into neural retinal cells[J].Recent Advances in Ophthalmology,2016,36(6):885.[doi:10.13389/j.cnki.rao.2016.0238]
[5]陶天畅,李根林.牛磺酸生物学特性及其在视网膜病变治疗中的应用[J].眼科新进展,2018,38(2):179.[doi:10.13389/j.cnki.rao.2018.0041]
　TAO Tian-Chang,LI Gen-Lin.Taurine for the treatment of retinopathy and its biochemical features[J].Recent Advances in Ophthalmology,2018,38(6):179.[doi:10.13389/j.cnki.rao.2018.0041]
[6]许雲,何媛.程序性坏死与视网膜疾病相关性的研究进展[J].眼科新进展,2020,40(3):284.[doi:10.13389/j.cnki.rao.2020.0067]
　XU Yun,HE Yuan.Research advance on the correlation between programmed necrosis and retinal diseases[J].Recent Advances in Ophthalmology,2020,40(6):284.[doi:10.13389/j.cnki.rao.2020.0067]
[7]惠靖雯,陈伟,季中琨,等.微脉冲阈值下半导体激光在视网膜疾病中的应用研究进展[J].眼科新进展,2020,40(6):597.[doi:10.13389/j.cnki.rao.2020.0137]
　HUI Jingwen,CHEN Wei,JI Zhongkun,et al.Progress and application of subthreshold diode micropulse laser in retinal diseases[J].Recent Advances in Ophthalmology,2020,40(6):597.[doi:10.13389/j.cnki.rao.2020.0137]
[8]周紫依,游志鹏.基因编辑治疗视网膜疾病的研究进展[J].眼科新进展,2021,41(5):495.[doi:10.13389/j.cnki.rao.2021.0103]
　ZHOU Ziyi,YOU Zhipeng.Research progress of gene editing for retinal diseases[J].Recent Advances in Ophthalmology,2021,41(6):495.[doi:10.13389/j.cnki.rao.2021.0103]
[9]姜百慧,项开来,秦秀虹,等.深度学习在视网膜疾病中的应用[J].眼科新进展,2021,41(7):688.[doi:10.13389/j.cnki.rao.2021.0143]
　JIANG Baihui,XIANG Kailai,QIN Xiuhong,et al.Progress in the application of deep learning in retinal diseases[J].Recent Advances in Ophthalmology,2021,41(6):688.[doi:10.13389/j.cnki.rao.2021.0143]
[10]刘晓晖,徐静,吴京.糖原合成酶激酶3β（GSK3β）参与调控视网膜疾病的研究进展[J].眼科新进展,2022,42(2):159.[doi:10.13389/j.cnki.rao.2022.0033]
　LIU Xiaohui,XU Jing,WU Jing.Research progress of glycogen synthase kinase 3 beta in the regulation of retinal diseases[J].Recent Advances in Ophthalmology,2022,42(6):159.[doi:10.13389/j.cnki.rao.2022.0033]

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81170885）；新乡医学院博士科研基金资助（编号：XYBSKYZZ2015010-505119）
更新日期/Last Update: 2017-06-28